Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast Cancer

June 22nd 2021

Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.

Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19

June 21st 2021

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial

June 18th 2021

Douglas W. Blayney, MD, presents data from the 2021 American Society of Clinical Oncology Annual Meeting on the final results from the phase 3 PROTECTIVE-2 trial of Plinabulin and Pegfilgrastim in breast cancer patients treated with high febrile neutropenia risk chemotherapy.

Dr. Blanter on Racial Disparities in Development of Distant Metastases in Breast Cancer

June 18th 2021

Julia Blanter, MD, discusses the risk of developing distant metastases after initial breast cancer diagnosis among Black vs White women.

Dr. Hoskins on the Impact of Race on Breast Cancer Outcomes

June 16th 2021

Kent Hoskins, MD, discusses the impact of race on breast cancer outcomes.

Oncology Leaves Its Mark on 2020 Research and Development Trends

June 16th 2021

Rates of clinical trial initiation, novel drug development, and collaborative research and development deals were oncology.

Burgeoning Breast Cancer Landscape Brings Hope for a Brighter Future

June 15th 2021

The expansion of HER2-directed treatments and formulations, the availability of CDK4/6 inhibitors, and the broad activity of sacituzumab govitecan-hziy is a testament to the successful development of personalized medicine in breast cancer.

Frontline Trastuzumab Deruxtecan Under Exploration With or Without Pertuzumab in HER2+ Breast Cancer

June 14th 2021

Fam-trastuzumab deruxtecan-nxki is under investigation with or without pertuzumab vs a standard-of-care regimen comprised of a taxane, trastuzumab, and pertuzumab in the frontline treatment of patients with HER2-positive metastatic breast cancer as part of the phase 3 DESTINY-Breast09 trial.

Dr. Bardia on Ongoing Research With Amcenestrant and Palbociclib in ER+/HER2- Advanced Breast Cancer

June 12th 2021

Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.

Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast Cancer

June 12th 2021

Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.

CTC Evaluation Fails to Demonstrate Functional Significance in HER2-Negative Breast Cancer

June 10th 2021

Although circulating tumor cell analysis of patients with HER2-negative metastatic breast cancer identified patients with CTC amplification, the utility of subsequent HER2-directed treatment with trastuzumab plus vinorelbine in this patient population was low.

Trastuzumab Duocarmazine Shows Superiority Over Physician’s Choice for HER2+ Breast Cancer

June 8th 2021

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

Advances in Metastatic HER2-Positive Breast Cancer

June 8th 2021

Dr Gradishar and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Treating Early-Stage HER2-Positive Breast Cancer

June 8th 2021

Dr Gradishar and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Examining the Unmet Needs in the Treatment of HER2-Positive Breast Cancer

June 8th 2021

In the first segment, Dr Gradishar and colleagues examine the unmet needs clinicians face despite recent advances in the treatment of patients with HER2-positive breast cancer.

Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC

June 7th 2021

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

Sacituzumab Govitecan Maintains Efficacy Benefit Over Chemo in Metastatic TNBC, Irrespective of Agent

June 7th 2021

The antibody-drug conjugate sacituzumab govitecan retained benefit in progression-free survival, overall survival, and objective response rate over physician’s choice of therapy, regardless of the chemotherapy agent used.

SD-101 Plus Pembrolizumab and Paclitaxel Yields Moderate Response Boost in High-Risk, HER2-Negative Breast Cancer

June 7th 2021

Treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel resulted in a non-statistically significant increase in estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer across 3 HER2-negative biomarker signature groups.

Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton

June 7th 2021

OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.

Ultralow Risk 70-Gene Signature Is Indicative of Excellent Survival Outcomes in Early-Stage Breast Cancer

June 6th 2021

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated have an excellent survival prognosis regardless of clinical risk.